LIquid BIopsies in Patients Presenting Non-small Cell Lung Cancer

Inclusion Criteria19

• COHORT 1
• Patients with histologically confirmed advanced non-small-cell lung carcinoma (stage IIIB/IV) regardless of the mutation status
• Inclusion at the time of diagnostic
• Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the institution with an available histopathological report
• Age ≥ 18 years
• Covered by a health insurance
• Signed consent
• Patients with histologically confirmed advanced non-small-cell lung carcinoma (stage IIIB/IV) with one of the following molecular anomalies: Epidermal Growth Factor Receptor (EGFR), B-Raf proto oncogene (BRAF) or Human Epidermal Growth Factor Receptor-2 (HER2) mutations, Anaplatsic Lymphoma Kinase (ALK) or ROS porto-oncogene 1 (ROS1) translocation, Mesenchymal-epithelial transition factor (MET) amplification, RET rearrangement.
• Inclusion at the time of diagnosis
• Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the institution with an available histopathological report
• Age ≥ 18 years
• Covered by a health insurance
• Signed consent
• Patients with histologically confirmed advanced non-small-cell lung carcinoma (stage IIIB/IV) whatever the mutational or PD-L1 status.
• Inclusion at the time of immunotherapy treatment initiation (1st or 2nd line)
• Realization of tumor biopsy at the institution (Centre Léon Bérard) or outside the institution with an available histopathological report
• Age ≥ 18 years
• Covered by a health insurance
• Signed consent